(Nimacimab)Biosimilar Reference Antibody-GS40473

货号：GS40473

Nimacimab (also known as BMS‑986141) is an investigational, human monoclonal antibody that targets the cannabinoid type 1 receptor (CB1R), a G protein‑coupled receptor (GPCR) primarily expressed in the central nervous system and peripheral tissues. Unlike small‑molecule CB1R antagonists that cross the blood‑brain barrier and cause neuropsychiatric side effects, nimacimab is designed to be peripherally restricted—it does not significantly penetrate the central nervous system. By selectively blocking CB1R in peripheral tissues (e.g., liver, adipose tissue, gastrointestinal tract), it aims to modulate metabolic pathways without central adverse effects. It is being developed for the treatment of metabolic disorders, particularly non‑alcoholic steatohepatitis (NASH) and obesity‑related complications.